Literature DB >> 569699

Differential effects of leucine and methionine enkephalin on morphine-induced analgesia, acute tolerance and dependence.

J L Vaught, A E Takemori.   

Abstract

Intracerebroventricular (40-80 microgram) or i.p. (5-20 mg/kg) injection of leucine enkephalin 15 min before or after s.c. morphine administration resulted in a marked, dose-dependent enhancement of morphine analgesia as measured by the mouse tail-flick assay. Further, i.p. injection of leucine enkephalin (5 mg/kg) enhanced the analgesia produced by methadone and levorphanol in the tail-flick assay but not that by nalorphine in the abdominal constriction assay. Met- but not leu-enkephalin was an active analgesic in the abdominal constriction assay with the doses used. (D-Ala2, D-leu5)-enkephalin (1 mg/kg) treatment also markedly enhanced morphine analgesia. Similarly, administration of leucine enkephalin enhanced the development of acute tolerance and dependence produced by a single dose of morphine. Methionine enkephalin had no effect on any of the pharmacological responses produced by morphine, methadone or levorphanol. Morphine brain levels of mice after treatment with leucine or methionine enkephalin were found to be no different than those of saline-treated control animals. These results suggest that leucine enkephalin may be an important and potent physiological modulator of narcotic efficacy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 569699

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  48 in total

1.  Mu and Delta opioid receptors activate the same G proteins in human neuroblastoma SH-SY5Y cells.

Authors:  A Alt; M J Clark; J H Woods; J R Traynor
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  Commentary on neostigmine interactions with non steroidal anti-inflammatory drugs by Miranda et al.

Authors:  Ronald J Tallarida
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

Review 3.  Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics.

Authors:  Subramaniam Ananthan
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

4.  Co-administration of δ- and μ-opioid receptor agonists promotes peripheral opioid receptor function.

Authors:  Cicely L Schramm; Christopher N Honda
Journal:  Pain       Date:  2010-12       Impact factor: 6.961

Review 5.  Development of delta opioid peptides as nonaddicting analgesics.

Authors:  R S Rapaka; F Porreca
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

Review 6.  Peripheral mechanisms of pain and analgesia.

Authors:  Christoph Stein; J David Clark; Uhtaek Oh; Michael R Vasko; George L Wilcox; Aaron C Overland; Todd W Vanderah; Robert H Spencer
Journal:  Brain Res Rev       Date:  2008-12-31

Review 7.  Investigational peptide and peptidomimetic μ and δ opioid receptor agonists in the relief of pain.

Authors:  Aswini Kumar Giri; Victor J Hruby
Journal:  Expert Opin Investig Drugs       Date:  2013-12-13       Impact factor: 6.206

8.  Prolonged kappa opioid receptor phosphorylation mediated by G-protein receptor kinase underlies sustained analgesic tolerance.

Authors:  Jay P McLaughlin; Lisa C Myers; Paul E Zarek; Marc G Caron; Robert J Lefkowitz; Traci A Czyzyk; John E Pintar; Charles Chavkin
Journal:  J Biol Chem       Date:  2003-11-03       Impact factor: 5.157

9.  Action of enkephalin analogues and morphine on brain acetylcholine release: differential reversal by naloxone and an opiate pentapeptide.

Authors:  K Jhamandas; M Sutak
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

10.  Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses.

Authors:  Jay P McLaughlin; Monica Marton-Popovici; Charles Chavkin
Journal:  J Neurosci       Date:  2003-07-02       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.